966 Feasibility of 5-FU therapeutic monitoring

• Published in: European journal of cancer (1990) Vol. 31; p. S201
• Main Authors: Coudert, B., de Gislain, C., Beltramo, Riedinger, J.M., Mayer, F., Bruchon, Y., Dumas, M., Fargeot, P., Guerrin, J.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01-11-1995
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(95)96215-Y

5-FV therapeutic monitoring was performed, in 26 patients with localized or disseminated epidermoïd tumour of various origin, during 64 chemotherapy cycles containing 5-FV 1000
mg/m
2 in continuous infusion (J1–J5) and CDDP (100
mg/m
2 J1 or 20
mg/m
2/j J1–J5). Blood samples were collected daily (8 a.m., 4 p.m.). 5-FV HPLC analysis used the method of Christophidis. Dose reduction of 5-FV was programmed according to the method of R. Fety using the J1–J2 and the J1–J5 5-FV area under the curve (AUC). An average of 2 cycles was administered.
During the 1st cycle: J1–J2 5-FV AUC averaged 15751 μg 1
−1 h
−1 ± 12309 (3902–56620) confirming the great interpatient variability. In 4 patients J1–J2 5-FV AUC > 20000 μg 1
−1 h
−1 obliged to cancel chemotherapy at β. J1–J5 5-FV AUC averaged 46161 μg 1
−1 h
−1
±
20020 (18380–90200). We observed a 5-FV accumulation process, characterised by an increase of daily 5-FV AUC in 18 patients. 5-FV dose reduction was scheduled in 27 cases and necessitated a further decrease during the chemotherapy cycle in 9 cases. 5-FV monitoring allowed a reduction in the toxicity which were less frequent for the cycles with J1–J2 5-FV AUC
<
20000
μg 1
−1 h
−1 or J1–J5 5-FV AUC <
30000
μg 1
−1 h
−1. Fourteen objective responses were obtained with 2 complete responses. J1–J5 5-FV AUC did not differ between responders and non responders.
These time consuming techniques must find their role during more prolonged chemotherapy.